申请人:Santen Pharmaceutical Co., Ltd.
公开号:US05087627A1
公开(公告)日:1992-02-11
A method for treatment of disorders of the cerebro-neural transmission system which comprises administering a compound of the formula (I) or a pharmaceutically acceptable salt thereof in a therapeutically effective amount, either alone or in admixture with one or more pharmaceutically acceptable excipients, ##STR1## wherein Ar or Ar' is unsubstituted or substituted phenyl or pyridyl; R is hydrogen, lower alkyl, lower alkoxy, halogen or lower alkylenedioxy; A is C.sub.1 -C.sub.6 alkylene; and n is 0 or 1. A compound of the formula (II) or a pharmaceutically acceptable salt thereof, ##STR2## wherein R.sup.1 is hydrogen or fluorine; R.sup.2 is hydrogen or fluorine; R.sup.3 is hydrogen, lower alkyl, lower alkoxy, halogen or lower alkylenedioxy; A is lower C.sub.1 -C.sub.6 alkylene, and n is 0 or 1, provided that at least one of R.sup.1 or R.sup.2 is fluorine.
一种治疗脑神经传输系统紊乱的方法,包括以治疗有效剂量给予式(I)的化合物或其药学上可接受的盐,单独或与一个或多个药学上可接受的赋形剂混合使用,其中Ar或Ar'为未取代或取代的苯基或吡啶基;R为氢、低碳酰基、低烷氧基、卤素或低碳酰二氧基;A为C.sub.1 -C.sub.6烷基;n为0或1。一种式(II)的化合物或其药学上可接受的盐,其中R.sup.1为氢或氟;R.sup.2为氢或氟;R.sup.3为氢、低碳酰基、低烷氧基、卤素或低碳酰二氧基;A为低C.sub.1 -C.sub.6烷基,n为0或1,但至少其中一种是氟。